DeDora Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$352K Sell
2,783
-107
-4% -$14.1K 0.08% 99
2026
Q1
$403K Hold
2,890
0.1% 88
2025
Q4
$355K Sell
2,890
-121
-4% -$14.7K 0.08% 96
2025
Q3
$334K Hold
3,011
0.08% 100
2025
Q2
$334K Buy
3,011
+1
+0% +$106 0.09% 99
2025
Q1
$337K Sell
3,010
-169
-5% -$17.4K 0.1% 95
2024
Q4
$294K Sell
3,179
-34
-1% -$3.06K 0.08% 100
2024
Q3
$269K Sell
3,213
-3,802
-54% -$290K 0.08% 101
2024
Q2
$481K Sell
7,015
-156
-2% -$10.4K 0.15% 83
2024
Q1
$525K Sell
7,171
-3,002
-30% -$231K 0.17% 78
2023
Q4
$824K Buy
10,173
+59
+0.6% +$4.59K 0.29% 63
2023
Q3
$758K Buy
10,114
+1,170
+13% +$90K 0.3% 62
2023
Q2
$689K Buy
8,944
+251
+3% +$20K 0.27% 71
2023
Q1
$721K Buy
8,693
+23
+0.3% +$1.91K 0.31% 69
2022
Q4
$744K Buy
8,670
+521
+6% +$41.3K 0.35% 61
2022
Q3
$503K Sell
8,149
-225
-3% -$14.2K 0.26% 70
2022
Q2
$518K Sell
8,374
-8,873
-51% -$549K 0.26% 69
2022
Q1
$1.02M Buy
+17,247
New +$1.1M 0.41% 52
2021
Q4
Sell
-15,044
Closed -$1.05M 73
2021
Q3
$1.05M Buy
15,044
+345
+2% +$24.2K 0.46% 47
2021
Q2
$1.01M Sell
14,699
-72
-0.5% -$4.81K 0.44% 49
2021
Q1
$955K Buy
14,771
+132
+0.9% +$8.51K 0.45% 48
2020
Q4
$853K Sell
14,639
-707
-5% -$42.7K 0.42% 55
2020
Q3
$970K Buy
15,346
+1,880
+14% +$130K 0.54% 48
2020
Q2
$1.04M Buy
13,466
+859
+7% +$65.8K 0.62% 42
2020
Q1
$942K Sell
12,607
-248
-2% -$17.1K 0.71% 41
2019
Q4
$835K Buy
12,855
+735
+6% +$47.9K 0.5% 51
2019
Q3
$768K Sell
12,120
-3,029
-20% -$198K 0.53% 48
2019
Q2
$1.02M Buy
15,149
+517
+4% +$34K 0.72% 40
2019
Q1
$951K Buy
14,632
+3,370
+30% +$224K 0.72% 37
2018
Q4
$704K Buy
11,262
+5,573
+98% +$390K 0.62% 42
2018
Q3
$439K Sell
5,689
-998
-15% -$75.4K 0.33% 54
2018
Q2
$474K Sell
6,687
-379
-5% -$26.8K 0.37% 56
2018
Q1
$533K Sell
7,066
-293
-4% -$23.3K 0.43% 50
2017
Q4
$527K Buy
+7,359
New +$559K 0.44% 47

Other funds holding GILD

DeDora Capital's GILD Position: Q2 2026 in Review

DeDora Capital reduced its Gilead Sciences (GILD) stake by 3.7% in Q2 2026, selling an estimated $14.1K and leaving 2,783 shares worth $352K. The position accounts for 0.08% of the portfolio, ranked #99.

DeDora Capital first reported a position in GILD in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.05M in Q3 2021. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • DeDora Capital held 2,783 shares of Gilead Sciences worth $352K as of Q2 2026.
  • DeDora Capital sold 107 Gilead Sciences shares in Q2 2026, an estimated $14.1K.
  • Gilead Sciences made up 0.08% of DeDora Capital's portfolio in Q2 2026, its #99 holding.
  • DeDora Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 34 quarters since.
  • DeDora Capital's Gilead Sciences position peaked at $1.05M in Q3 2021.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on DeDora Capital's 13F filing for Q2 2026, filed 13 Jul 2026.